AI in Medicine — Cancer & Rare Disease — 2026-10-03 (Sat)

Latest news on AI and cancer treatment

Overview

- Movements are centered on the implementation of diagnostics, imaging, and pathology, and corporate alliances, with notable developments being the expansion of breast cancer screening AI in the United States, distribution infrastructure for pathology AI, and collaborations in the development of biomarkers/CDx. - In drug discovery, there are announcements of alliances and comments from the industry that ``AI alone is not enough.'' In terms of regulations, the FDA plans to prioritize guidelines for AI and surgical robots next year. - Numerical indicators of clinical efficacy cannot be ascertained from headlines.

Breast cancer

- Everlywell rolls out Clairity AI in the US (pharmaphorum). The target and performance are unclear from the headline. - Shasta Regional Medical Center begins offering mammography and DEXA using AI technology (Record Searchlight). This is an introduction example, and performance data is not included in the heading. - Reported that SimBioSys will use AI to treat breast cancer (28/22 News). It is unclear from the headline what was shown. - Natalia Oprea considers introducing AI support tools in breast cancer treatment (Cinderella Project, Oncodaily). - Evidence level: All unknown (heading only).

lung cancer

- Headings specific to lung cancer cannot be confirmed. - As a related headline, PumasAI introduced AI, scientific machine learning, and pharmacometrics research at ACoP 2026 (no cancer type listed). n1.care announces AI clinical intelligence platform (no cancer type listed). Expansion of CDx collaboration between CellCarta and Imagene AI (cancer type not specified).

Malignant brain tumor

No applicable information

Leukemia/lymphoma

No applicable information

Colon cancer/digestive organ

- Report that AI predicts the "hidden spread" of colorectal cancer from images before surgery (Bioengineer.org). The number of target cases, precision, and study design are unclear from the headline.

Rare cancer

- No relevant information (no headings specific to rare cancers). - For reference, there is a report that AI can detect residual cancer by reading the polarization of light in dog tumors (Bioengineer.org). It is for animals and is considered to be equivalent to preclinical, but there is no description of the stage in the heading.

Diagnosis/Pathology/Image

- Leica Biosystems adds Tempus pathology products to Aperio AI Store (Manufacturing Chemist). This is an expansion of the distribution infrastructure, and the measurement target and performance are unknown. - CellCarta and Imagene AI collaborate on biomarker/CDx development (Genome Web, Select Science). - Essentials of post-implementation monitoring of radiology AI (diagnosticimaging.com). - Research shows that training gaps for radiology residents can be identified using AI tools (Imaging Technology News). Research design unknown.

Treatment selection/drug discovery

- BioMarin partners with Profluent on AI drug discovery (article on simplywall.st). The target disease and development stage are unclear from the headline. Parts related to stock valuation are not covered. - Valo's Brian Alexander said that AI will not solve drug discovery unless human biology is brought upstream (biggo). Opinion, not data.

Regulations/Approval

- FDA plans to prioritize guidance on AI and surgical robots next year (MedTech Dive). Classification is a "priority policy of guidelines" and is not an approval or designation. The item name is not in the heading. - Headings regarding EMA and PMDA cannot be confirmed.

Clinical trial implementation status

- No applicable information because ClinicalTrials.gov data is not included in the input. We do not make assumptions about the number or condition of cases.

Japanese movements

No applicable information

Remarks from VIPs

- The list of important people being tracked is empty. - Reference: Valo's Brian Alexander's statement is listed in [9]. The title is not in the heading and is unknown.

Latest news on AI and rare and intractable diseases

Overview

This time, we collected four articles, all of which are headlines from company/stock price analysis articles on the investment information site (simplywall.st). It is mainly active in the areas of drug discovery, gene therapy, and genome analysis. There are no headlines indicating the effect of shortening diagnosis or any changes in the system.

Diagnosis of rare diseases

No applicable information

Gene analysis/genome

- It was reported that Tempus AI (TEM) is undergoing validation of its valuation as it expands into whole genome sequencing (headline only. Source is an investment information site, not clinical evidence). - There is no information in the headlines indicating clinical outcomes such as mutation interpretation accuracy, detection rate, and diagnosed diseases.

Development of therapeutic drugs

- Johnson & Johnson (JNJ): An article discussing the implications of gene therapy and AI-based drug repurposing. The target disease, development stage, and data cannot be confirmed from the headline. - BioMarin Pharmaceutical (BMRN): Following its partnership with Profluent AI, there is one article valuing the stock as "potentially 35% undervalued," and one article discussing what the AI drug discovery partnership means for shareholders. The target disease or development stage of the partnership cannot be confirmed from the headline. - All three articles are reviews from the perspective of corporate value and shareholders, and no evidence of efficacy or safety (preclinical studies, case reports, clinical trials, etc.) is indicated in the headlines.

Nerve/muscular diseases

No applicable information

Immunology/Collagen disease

No applicable information

Rare metabolic/endocrine diseases

No relevant information (BioMarin's affiliated diseases are not listed in the heading, and it is not possible to confirm whether they are designated intractable diseases)

System/Patient Support

No applicable information

Japanese movements

No applicable information

Remarks from VIPs

No relevant information (list of important people being tracked is empty)

Points to note

All four articles this time are about stocks and company evaluations, and do not represent the results of diagnosis or treatment of rare or intractable diseases. Since there is no disease name in the heading, it is not possible to compare it with designated intractable diseases (348 diseases), and no notification number is attached.